(Q38085501)

28 August 2017

title

Targeting pathological B cell receptor signalling in lymphoid malignancies (English)

1 reference

28 August 2017

Ryan M Young

1

1 reference

28 August 2017

Louis M Staudt

series ordinal

2

1 reference

28 August 2017

publication date

1 March 2013

1 reference

Nature Reviews Drug Discovery

28 August 2017

published in

1 reference

28 August 2017

volume

12

1 reference

28 August 2017

issue

3

1 reference

28 August 2017

page(s)

229-243

1 reference

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

28 August 2017

cites work

1 reference

Receptors, subcellular compartments and the regulation of peripheral B cell responses: the illuminating state of anergy

31 March 2020

1 reference

Antigen receptor tail clue.

31 March 2020

1 reference

Essential role of Src-family protein tyrosine kinases in NF-kappaB activation during B cell development

31 March 2020

1 reference

Syk protein-tyrosine kinase is regulated by tyrosine-phosphorylated Ig alpha/Ig beta immunoreceptor tyrosine activation motif binding and autophosphorylation

31 March 2020

1 reference

The B-cell antigen receptor signals through a preformed transducer module of SLP65 and CIN85

31 March 2020

1 reference

PKC beta regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1

31 March 2020

1 reference

Phosphoinositide 3-kinase: diverse roles in immune cell activation

31 March 2020

1 reference

B cell antigen receptor signaling 101.

31 March 2020

1 reference

31 March 2020

1 reference

Pathogenesis of human B cell lymphomas

31 March 2020

1 reference

In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death.

31 March 2020

1 reference

Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer

31 March 2020

1 reference

PI3 kinase signals BCR-dependent mature B cell survival

31 March 2020

1 reference

ITAM-mediated tonic signalling through pre-BCR and BCR complexes

31 March 2020

1 reference

Essential function for the GTPase TC21 in homeostatic antigen receptor signaling.

31 March 2020

1 reference

Differential binding activity of ARH1/TAM motifs

31 March 2020

1 reference

Evidence for a preformed transducer complex organized by the B cell antigen receptor

31 March 2020

1 reference

Oligomeric organization of the B-cell antigen receptor on resting cells

31 March 2020

1 reference

Predominant autoantibody production by early human B cell precursors

31 March 2020

1 reference

Regulation of autoreactive antibodies

31 March 2020

1 reference

Molecular underpinning of B-cell anergy

31 March 2020

1 reference

Anergic responses characterize a large fraction of human autoreactive naive B cells expressing low levels of surface IgM.

31 March 2020

1 reference

Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy

31 March 2020

1 reference

Suppression of phosphatidylinositol 3,4,5-trisphosphate production is a key determinant of B cell anergy

31 March 2020

1 reference

Mechanisms of B-cell lymphoma pathogenesis

31 March 2020

1 reference

Origin of chromosomal translocations in lymphoid cancer

31 March 2020

1 reference

Burst-enhancing role of the IgG membrane tail as a molecular determinant of memory.

31 March 2020

1 reference

Enhancement and suppression of signaling by the conserved tail of IgG memory-type B cell antigen receptors

31 March 2020

1 reference

Multiple layers of B cell memory with different effector functions

31 March 2020

1 reference

A closer look at follicular lymphoma

31 March 2020

1 reference

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

31 March 2020

1 reference

Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma

31 March 2020

1 reference

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

31 March 2020

1 reference

The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma.

31 March 2020

1 reference

A loss-of-function RNA interference screen for molecular targets in cancer

31 March 2020

1 reference

Oncogenic CARD11 mutations in human diffuse large B cell lymphoma

31 March 2020

1 reference

Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells

31 March 2020

1 reference

The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes

31 March 2020

1 reference

Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation

31 March 2020

1 reference

Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement

31 March 2020

1 reference

Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas

31 March 2020

1 reference

The molecular assembly and organization of signaling active B-cell receptor oligomers.

31 March 2020

1 reference

CARMA1, BCL-10 and MALT1 in lymphocyte development and activation.

31 March 2020

1 reference

Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation

31 March 2020

1 reference

Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities.

31 March 2020

1 reference

Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection.

31 March 2020

1 reference

The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis

31 March 2020

1 reference

Malignant pirates of the immune system

31 March 2020

1 reference

Autoimmune and Chronic Inflammatory Disorders and Risk of Non-Hodgkin Lymphoma by Subtype

31 March 2020

1 reference

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia

31 March 2020

1 reference

Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia

31 March 2020

1 reference

Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.

31 March 2020

1 reference

Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies

31 March 2020

1 reference

Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity

31 March 2020

1 reference

Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation

31 March 2020

1 reference

Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin

31 March 2020

1 reference

The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia

31 March 2020

1 reference

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

31 March 2020

1 reference

Incidence of potential glycosylation sites in immunoglobulin variable regions distinguishes between subsets of Burkitt's lymphoma and mucosa-associated lymphoid tissue lymphoma

31 March 2020

1 reference

Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor.

31 March 2020

1 reference

Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins

31 March 2020

1 reference

Ig gene diversification and selection in follicular lymphoma, diffuse large B cell lymphoma and primary central nervous system lymphoma revealed by lineage tree and mutation analyses

31 March 2020

1 reference

Self-antigen recognition by follicular lymphoma B-cell receptors

31 March 2020

1 reference

B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression

31 March 2020

1 reference

Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics

31 March 2020

1 reference

Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis

31 March 2020

1 reference

Induction of apoptosis in fibroblasts by c-myc protein

31 March 2020

1 reference

SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma

31 March 2020

1 reference

R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation

31 March 2020

1 reference

Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing

31 March 2020

1 reference

Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs

31 March 2020

1 reference

Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia

31 March 2020

1 reference

SF3B1 and other novel cancer genes in chronic lymphocytic leukemia

31 March 2020

1 reference

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

31 March 2020

1 reference

The SYK tyrosine kinase: a crucial player in diverse biological functions

31 March 2020

1 reference

Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells

31 March 2020

1 reference

B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.

31 March 2020

1 reference

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target

31 March 2020

1 reference

The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling

31 March 2020

1 reference

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

31 March 2020

1 reference

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

31 March 2020

1 reference

Specific Inhibition of Spleen Tyrosine Kinase Suppresses Leukocyte Immune Function and Inflammation in Animal Models of Rheumatoid Arthritis

31 March 2020

1 reference

SYK inhibition and response prediction in diffuse large B-cell lymphoma

31 March 2020

1 reference

Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice

31 March 2020

1 reference

Impaired expansion of mouse B cell progenitors lacking Btk.

31 March 2020

1 reference

Defective B cell development and function in Btk-deficient mice

31 March 2020

1 reference

Tyrosine kinases and their substrates in B lymphocytes

31 March 2020

1 reference

Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases

31 March 2020

1 reference

Regulation of Btk by Src family tyrosine kinases

31 March 2020

1 reference

Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain

31 March 2020

1 reference

Four tyrosine residues in phospholipase C-gamma 2, identified as Btk-dependent phosphorylation sites, are required for B cell antigen receptor-coupled calcium signaling

31 March 2020

1 reference

Activation of phospholipase Cgamma2 by tyrosine phosphorylation

31 March 2020

1 reference

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

31 March 2020

1 reference

Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

31 March 2020

1 reference

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase

31 March 2020

1 reference

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

31 March 2020

1 reference

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

31 March 2020

1 reference

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

31 March 2020

1 reference

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

31 March 2020

1 reference

Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases

31 March 2020

1 reference

PI3K pathway alterations in cancer: variations on a theme

31 March 2020

1 reference

PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances

31 March 2020

1 reference

mTOR signaling in growth control and disease

31 March 2020

1 reference

Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.

31 March 2020

1 reference

Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma

31 March 2020

1 reference

Antigen receptor signalling: a distinctive role for the p110delta isoform of PI3K.

31 March 2020

1 reference

The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development.

31 March 2020

1 reference

PI3K/p110{delta} is a novel therapeutic target in multiple myeloma

31 March 2020

1 reference

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

31 March 2020

1 reference

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

31 March 2020

1 reference

The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

31 March 2020

1 reference

Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape

31 March 2020

1 reference

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

31 March 2020

1 reference

A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma

31 March 2020

1 reference

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

31 March 2020

1 reference

PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.

31 March 2020

1 reference

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma

31 March 2020

1 reference

Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma

31 March 2020

1 reference

T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20

31 March 2020

1 reference

The proteolytic activity of the paracaspase MALT1 is key in T cell activation

31 March 2020

1 reference

Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines.

31 March 2020

1 reference

Prostate stem cell antigen is overexpressed in prostate cancer metastases

31 March 2020

1 reference

Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.

31 March 2020

1 reference

Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls

31 March 2020

1 reference

Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

31 March 2020

1 reference

Oncogenically active MYD88 mutations in human lymphoma

31 March 2020

1 reference

MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type

31 March 2020

1 reference

Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma

31 March 2020

1 reference

BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas

31 March 2020

1 reference

MYD88 somatic mutations in MALT lymphomas

31 March 2020

1 reference

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

31 March 2020

1 reference

Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors

31 March 2020

1 reference

Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response

31 March 2020

1 reference

Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma

31 March 2020

1 reference

Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.

31 March 2020

1 reference

A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma.

31 March 2020

1 reference

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia

31 March 2020

1 reference

12 December 2020

Leukemia and auto-immunization- some possible relationships.

1 reference

12 December 2020

Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.

1 reference

12 December 2020

Burkitt's lymphoma is a malignancy of mature B cells expressing somatically mutated V region genes

1 reference

12 December 2020

DNA fiber fluorescence in situ hybridization analysis of immunoglobulin class switching in B-cell neoplasia: aberrant CH gene rearrangements in follicle center-cell lymphoma

1 reference

12 December 2020

1 reference

12 December 2020

Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD3937

1 reference

28 August 2017

1 reference